| __timestamp | ADMA Biologics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 9335772 |
| Thursday, January 1, 2015 | 4311461 | 999000 |
| Friday, January 1, 2016 | 6360761 | 978000 |
| Sunday, January 1, 2017 | 29164321 | 952000 |
| Monday, January 1, 2018 | 42194635 | 956000 |
| Tuesday, January 1, 2019 | 39504238 | 8122999 |
| Wednesday, January 1, 2020 | 61291426 | 8712000 |
| Friday, January 1, 2021 | 79769341 | 13980000 |
| Saturday, January 1, 2022 | 118814535 | 21135000 |
| Sunday, January 1, 2023 | 169273000 | 10755000 |
Unleashing insights
In the evolving landscape of biotechnology, understanding cost dynamics is crucial. From 2014 to 2023, ADMA Biologics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trajectories in their cost of revenue. ADMA Biologics has experienced a staggering increase of over 4,400%, starting from approximately $3.7 million in 2014 to nearly $169 million in 2023. This growth reflects their expanding operations and market reach. In contrast, Iovance Biotherapeutics has maintained a more stable cost structure, with a modest increase of around 15% over the same period, peaking at about $21 million in 2022. This stability suggests a strategic focus on cost management while scaling their innovative therapies. These insights highlight the diverse strategies within the biotech sector, where companies balance growth and cost efficiency to drive success.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs ADMA Biologics, Inc.
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
ADMA Biologics, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Veracyte, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs Evotec SE
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.